Pharma: Keine Käufer gefunden - drei Biontech-Werke machen dicht
In der Corona-Pandemie verdiente Biontech Milliarden - damit ist es vorbei. Das Unternehmen muss sparen, baut Personal ab. Nun ist klar, dass an drei Standorten die Tore endgültig schließen.
Despite months of unsuccessful efforts, three German sites of Biontech are set to close soon, affecting around 1,800 employees. Biontech explained the closures were primarily due to the challenging market and investment environment. In Marburg, the site, which has a rich history and was once acquired from the Swiss pharmaceutical company Novartis, will cease operations by the end of 2028.
The Idar-Oberstein site, where therapies for early clinical development phases are produced, will shut down by the end of the same year. Tübingen, home to the former competitor Curevac, will close by the end of 2027. Biontech claimed it had held confidential talks with potential buyers, including international, national, and medium-sized companies and investors.
However, no sales were made. The company has been undergoing a transformation and restructuring, focusing on oncology and immunotherapies based on mRNA and monoclonal antibodies. This shift has led to significant losses, with a 1.35 billion euro deficit in the first half of this year. Biontech's founders, Ugur Sahin and Özlem Türeci, will leave the company at the end of the year to establish a new venture called Arife, headquartered in Mainz, where they plan to focus on developing the next generation of mRNA-based medicines.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
